Synthon B.v.

Lisardo Alvarez Fernandez

Luis Nogueiras Nieto

Rohit Kumar

Jose Velada Calzada

Marta Vivancos Martinez

Deepak Murpani

Sara Fradera Gelabert

Manuel Gago Guillan

Rolf Keltjens

Raymond Westheim

Jacobus Theodorus Henricus Van Eupen

Petr Mitas

Agnes Fernandez Pena

Bohumil Dymacek

Sonia Garcia Jimenez

Katerina Jelinkova

Manolo Gago Guillan

Luis Noguiras Nieto

The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent. The invention further relates to the use of said tablet as a medicament, particularly in the treatment of immune thrombocytopenia (ITP), thrombocytopenia in patients with chronic hepatitis C virus (HCV) and severe aplastic anaemia (SAA).

Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)

The present invention relates to an immediate release tablet composition comprising axitinib form IV characterized by an XRPD pattern comprising the peaks at about 8.9, 12.0, 14.6, 15.2, 15.7, 17.8, 19.1, 20.6, 21.6, 23.2, 24.2, 24.9, 26.1 and 27.5±0.1 degrees 2θ, when measured with Cu Kα1 radiation and one or more pharmaceutically acceptable excipients, wherein the composition exhibits a dissolution rate between 40% and 70% in 30 minutes when tested in 900 ml 0.01 N hydrochloric acid pH 2.0 at 37° C., 75 rpm in a USP apparatus II.

Pharmaceutical composition comprising axitinib

The present invention relates to lenvatinib besylate, its crystalline forms and processes for making them. Furthermore, to a pharmaceutical composition comprising a therapeutically effective dose of lenvatinib besylate.

Crystalline forms and processes of lenvatinib besylate

The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1:1.5 to 1:5.

Pharmaceutical composition comprising Lenvatinib mesylate

The present invention relates to a tablet composition for oral administration of abiraterone acetate, particularly to pharmaceutical granulates and tablets giving immediate release of abiraterone acetate in the stomach.

Tablet compositions comprising abiraterone acetate

The present invention relates to a pharmaceutical granulate composition comprising Palbociclib free base, having improved bioavailability.

Pharmaceutical composition comprising Palbociclib

The present invention relates to a pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of multiple myeloma.

Pharmaceutical composition comprising pomalidomide

The present invention relates to a pharmaceutical composition comprising amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, with a synthetic antioxidant and one or more pharmaceutically acceptable excipients. The invention further relates to the process to manufacture such a compositions and the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodyplastic syndromes.

Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant

The present invention relates to a tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenstr&#xf6;m's macroglobulinaemia (WM).

Pharmaceutical composition comprising ibrutinib

The present invention relates to a pharmaceutical composition comprising a physical mixture of sacubitril sodium and valsartan disodium, wherein the X-ray powder diffraction pattern of valsartan disodium comprises characteristic peaks at the following 2 theta (&#xb1;0.2) angles: 4.70&#xb0;, 9.29&#xb0;, 22.34&#xb0;, measured using a Cu K&#x3b1; radiation. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of heart failure.

Pharmaceutical composition comprising sacubitril and valsartan

The present invention relates to a pharmaceutical composition, particularly a modified release tablet composition comprising mirabegron or a pharmaceutically acceptable salt thereof and to a process for preparing such a composition.

Modified release tablet composition comprising mirabegron

The present invention relates to a pharmaceutical composition comprising an amorphous adsorbate of lenalidomide, or a pharmaceutically acceptable salt thereof, on a porous carrier and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of multiple myeloma and myelodysplastic syndromes.

Pharmaceutical composition comprising amorphous lenalidomide

The present invention relates to a pharmaceutical composition comprising an inclusion complex of amorphous lenalidomide, or a pharmaceutically acceptable salt thereof, in non-substituted &#x3b2;-cyclodextrin and one or more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of in the treatment of multiple myeloma and myelodysplastic syndromes.

Growing community of inventors

Sant Boi de Llobregat, Spain

Lisardo Alvarez Fernandez